8394
S. R. Hanson et al. / Bioorg. Med. Chem. 14 (2006) 8386–8395
6. Roberton, A. M.; Wright, D. P. Can. J. Gastroenterol.
1997, 11, 361–366.
7. Dhoot, G. K.; Gustafsson, M. K.; Ai, X.; Sun, W.;
Standiford, D. M.; Emerson, C. P., Jr. Science 2001, 293,
1663–1666.
8. Schirmer, A.; Kolter, R. Chem. Biol. 1998, 5, R181–
R186.
9. Uhlhorn-Dierks, G.; Kolter, T.; Sandhoff, K. Angew.
Chem., Int. Ed. 1998, 37, 2453–2455.
10. Sardiello, M.; Annunziata, I.; Roma, G.; Ballabio, A.
Hum. Mol. Genet. 2005, 14, 3203–3217.
11. Lukatela, G.; Krauss, N.; Theis, K.; Selmer, T.; Giesel-
mann, V.; von Figura, K.; Saenger, W. Biochemistry 1998,
37, 3654–3664.
substrate, p-NPS, or an exogenous nucleophile was add-
ed to the incubation mixture. In order to determine if a
sulfatase substrate provided protection against inhibitor
inactivation, the concentration of p-NPS was varied
from 0.025 to 1 mM in the presence of inhibitor. For
studying the effects that exogenous nucleophiles have
on inactivation rates, b-mercaptoethanol (cysteine-type
behavior), imidazole (histidine-like behavior), and lysine
were added to a final concentration of 1 mM in the pres-
ence of inhibitor. In all cases, inactivation rates were
compared with those of PARS and inhibitor-only
controls.
12. Parenti, G.; Meroni, G.; Ballabio, A. Curr. Opin. Genet.
Dev. 1997, 7, 386–391.
13. Nussbaumer, P.; Billich, A. Med. Res. Rev. 2004, 24, 529–
576.
14. Ai, X.; Do, A.-T.; Lozynska, O.; Kusche-Gullberg, M.;
Lindahl, U.; Emerson, C. P., Jr. J. Cell Biol. 2003, 162,
341–351.
15. Lai, J.; Chien, J.; Staub, J.; Avula, R.; Greene, E. L.;
Matthews, T. A.; Smith, D. I.; Kaufmann, S. H.;
Roberts, L. R.; Shridhar, V. J. Biol. Chem. 2003, 278,
23107–23117.
4.2.5. Recovery of activity following inactivation. PARS
(10 lg/mL) was mixed with 5 mM inhibitor. Additional-
ly, control samples of PARS incubated alone, as well as,
in the presence of 5 mM p-NPS were performed. After
an overnight incubation, the samples were subjected to
extensive dialysis in microdialysis units (Pierce). Dialysis
buffer (1 L, 100 mM Tris buffer, pH 8.9) was changed
every 3 h for the first 12 h and then every 12 h for the
remainder of the experiment. At various time points,
5 lL aliquots of dialysate were removed and diluted 1/
20 in sulfatase assay buffer to determine catalytic activ-
ity. Activities were normalized to percentage activity of
untreated and undialyzed protein standard.
16. Roberton, A. M.; Corfield, A. P. Mucin Degradation
and its Significance in Inflammatory Conditions of the
GI Tract; Kluwer Academic: Great Britain, 1999, pp
222–261.
17. Roberton, A. M.; Wiggins, R.; Horner, P. J.; Greenwood,
R.; Crowley, T.; Fernandes, A.; Berry, M.; Corfield, A. P.
J. Clin. Microbiol. 2005, 43, 5504–5508.
18. Winum, J. Y.; Scozzafava, A.; Montero, J. L.; Supuran, C.
T. Med. Res. Rev. 2005, 25, 186–228.
Acknowledgments
This work was supported by the NIH and the Skaggs
Institute for Chemical Biology. The authors kindly
thank Professor Michael Kertesz for providing the
PARS gene. S.R.H. acknowledges predoctoral support
from the ARCS foundation. L.J.W. thank the Skaggs
Institute of Chemical Biology for a postdoctoral
fellowship.
19. Abeles, R. H.; Maycock, A. L. Accounts of Chemical
Research. 1976, 9, 313–319.
20. Beil, S.; Kehrli, H.; James, P.; Staudenmann, W.; Cook,
A. M.; Leisinger, T.; Kertesz, M. A. Eur. J. Biochem. 1995,
229, 385–394.
21. Boltes, I.; Czapinska, H.; Kahnert, A.; von Bulow, R.;
Dierks, T.; Schmidt, B.; vonFigura, K.; Kertesz, M. A.;
Uson, I. Structure 2001, 9, 483–491.
22. Speers, A. E.; Cravatt, B. F. Chem. Biol. 2004, 11, 535–
546.
References and notes
23. Cesaro-Tadic, S.; Lagos, D.; Honegger, A.; Rickard, J. H.;
Partridge, L. J.; Blackburn, G. M.; Pluckthun, A. Nat.
Biotechnol. 2003, 21, 679–685.
24. O’Brien, P. J.; Herschlag, D. J. Am. Chem. Soc. 1998, 120,
12369–12370.
25. Liu, Y.; Lien, I. F. F.; Ruttgaizer, S.; Dove, P.; Taylor, S.
D. Org. Lett. 2004, 6, 209–212.
26. von Bulow, R.; Schmidt, B.; Dierks, T.; von Figura, K.;
Uson, I. J. Mol. Biol. 2001, 305, 269–277.
27. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L.
J. Med. Chem. 1994, 37, 219–221.
1. Hanson, S. R.; Best, M. D.; Wong, C. H. Angew. Chem.,
Int. Ed. 2004, 43, 5736–5763.
2. Neufeld, E. F. M. J.; Muenzer, J. The Mucopolysacchari-
doses, 8th ed.. In The Metabolic and Molecular Bases of
Inherited Disease; Scriver, C. R., Beaudet, A. L., Sly, W.
S., Valle, D., Eds.; McGraw-Hill: New York, 1999; Vol.
III, pp 3421–3452.
3. Ballabio, A.; Shapiro, L. J. Steroid Sulfatase Deficiency
and X-linked Ichthyosis, 8th ed.. In The Metabolic and
Molecular Bases of Inherited Disease; Scriver, C. R.,
Beaudet, A. L., Sly, W. S., Valle, D., Eds.; McGraw-Hill:
New York, 1999; Vol. III, pp 4241–4261.
28. Hernandez-Guzman, F. G.; Higashiyama, T.; Pangborn,
W.; Osawa, Y.; Ghosh, D. J. Biol. Chem. 2003, 278,
22989–22997.
4. von Figura, K.; Gieselmann, V.; Joeken, J. Metachromatic
Leukodystrophy, 8th ed.. In The Metabolic and Molecular
Bases of Inherited Disease; Scriver, C. R., Beaudet, A. L.,
Sly, W. S., Valle, D., Eds.; McGraw-Hill: New York,
1999; Vol. III, pp 3695–3724.
5. Hopwood, J. J.; Ballabio, A. Multiple Sulfatase Deficiency
and the Nature of the Sulfatase Family, 8th ed.. In The
Metabolic and Molecular Bases of Inherited Disease;
Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D.,
Eds.; McGraw-Hill: New York, 1999; Vol. III, pp 3725–
3732.
29. Purohit, A.; Williams, G. J.; Howarth, N. M.; Potter,
B. V. L.; Reed, M. J. Biochemistry 1995, 34, 11508–
11514.
30. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.;
Potter, B. V. L. Chem. Biol. 2000, 7, 773–791.
31. Ahmed, S.; James, K.; Owen, C. P.; Patel, C. K.; Sampson,
L. Bioorg. Med. Chem. Lett. 2002, 12, 1279–1282.
32. Peters, R. H.; Chao, W.-R.; Sato, B.; Shigeno, K.; Zaveri,
N. T.; Tanabe, M. Steroids 2003, 68, 97–110.
33. Kitz, R.; Wilson, I. B. J. Biol. Chem. 1962, 237, 3245–
3249.